Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04280A1007

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a United States-based company focused on developing innovative medicines to treat challenging diseases. Among its diverse pipeline of products are Plozasiran, Zodasiran, ARO-PNPLA3, ARO-RAGE, and ARO-MUC5AC, targeting conditions like hypertriglyceridemia, dyslipidemia, and pulmonary diseases.

Additionally, Arrowhead Pharmaceuticals is actively working on treatments such as ARO-MMP7 for idiopathic pulmonary fibrosis, ARO-DUX4 for muscular dystrophy, ARO-SOD1 for ALS, and ARO-C3 for complement-mediated renal diseases, showcasing a commitment to addressing a wide range of health issues.

Collaborating with industry leaders like Janssen Pharmaceuticals, Takeda Pharmaceutical, Amgen, and GlaxoSmithKline, Arrowhead Pharmaceuticals leverages its expertise to advance treatments like JNJ-3989 for hepatitis B, Olpasiran for reducing apolipoprotein A production, and Fazirsiran for liver disease associated with alpha-1 antitrypsin deficiency.

Established in 2003 and located in Pasadena, California, Arrowhead Pharmaceuticals is dedicated to pushing the boundaries of medical innovation. To learn more about their work, visit their website at https://arrowheadpharma.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends

ARWR Stock Overview

Market Cap in USD 3,235m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1993-06-16

ARWR Stock Ratings

Growth 5y -0.67
Fundamental -8.50
Dividend -
Rel. Performance vs Sector -3.33
Analysts 4.21/5
Fair Price Momentum 19.56 USD
Fair Price DCF -

ARWR Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

ARWR Growth Ratios

Growth 12m -26.03%
Growth Correlation 12m -34%
Growth Correlation 3m -66%
CAGR 5y 3.99%
Sharpe Ratio 12m -0.50
Alpha vs SP500 12m -53.68
Beta vs SP500 5y weekly 1.29
ValueRay RSI 5.16
Volatility GJR Garch 1y 63.38%
Price / SMA 50 -22.84%
Price / SMA 200 -23.45%
Current Volume 1149.6k
Average Volume 20d 801.8k

External Links for ARWR Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of ARWR stocks?
As of April 18, 2024, the stock is trading at USD 22.53 with a total of 1,149,585 shares traded.
Over the past week, the price has changed by -11.26%, over one month by -19.94%, over three months by -33.85% and over the past year by -28.11%.
What is the forecast for ARWR stock price target?
According to ValueRays Forecast Model, ARWR Arrowhead Pharmaceuticals will be worth about 22 in April 2025. The stock is currently trading at 22.53. This means that the stock has a potential downside of -2.53%.
Issuer Forecast Upside
Wallstreet Target Price 55.4 145.8%
Analysts Target Price 55.6 146.6%
ValueRay Target Price 22 -2.53%